Founded Year
1999Stage
Dead | DeadAbout Quantum Leap Innovations
Quantum Leap Innovations is a technology company developing and deploying software products focused on the transformation of data into information and information into knowledge. The company's work is based on distributed computing, intelligent agents, and automated knowledge discovery technologies.
Quantum Leap Innovations Patents
Quantum Leap Innovations has filed 19 patents.
The 3 most popular patent topics include:
- Chemical processes
- Glass compositions
- Electromagnetic spectrum

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
8/30/2021 | 5/23/2023 | Grant |
Application Date | 8/30/2021 |
---|---|
Grant Date | 5/23/2023 |
Title | |
Related Topics | |
Status | Grant |
Latest Quantum Leap Innovations News
Dec 1, 2011
Quantum Leap Appoints Prof of Management December 1, 2011 By Angela Sormani Delaware Technology Park-headquartered Quantum Leap has appointed Michael A. Cusumano to its board of directors. Cusumano is the sloan management review distinguished professor of management at the Massachusetts Institute of Technology’s Sloan School of Management, with a joint appointment in the MIT Engineering Systems Division. PRESS RELEASE Quantum Leap Innovations announced today the appointment of Michael A. Cusumano to their Board of Directors. Michael Cusumano is the Sloan Management Review Distinguished Professor of Management at the Massachusetts Institute of Technology’s Sloan School of Management, with a joint appointment in the MIT Engineering Systems Division. His seminal 2010 book, STAYING POWER, covers six enduring principles for managing strategy and innovation in an uncertain world. “We are honored to have someone of Dr. Cusamano’s stature agree to join our board,” said Quantum Leap founder and CEO Joseph Budner Elad. “His support validates our vision of Pattern Based Analytics and the importance of our technology in today’s uncertain world.” “It is with great pleasure and excitement that I join the Quantum Leap board,” says Dr. Cusumano. “I have known the principals in the company for many years and have closely followed the evolution of their work in data analysis. The pattern-based analytics approach took years to develop. It significantly improves our ability to visualize and make sense of complex data sets and then apply these insights to a wide variety of business and other applications.” About Michael Cusumano: Michael Cusumano specializes in strategy, product development, and entrepreneurship in the computer software industry, as well as automobiles and consumer electronics. He teaches courses on The Software Business and Digital Platforms as well as Strategic Management and Managing Technological Innovation and Entrepreneurship. Professor Cusumano earned his B.A. degree from Princeton and his Ph.D. from Harvard. He completed a postdoctoral fellowship in Production and Operations Management at the Harvard Business School. He is fluent in Japanese and has lived and worked in Japan for seven years. He received two Fulbright Fellowships and a Japan Foundation Fellowship for studying at Tokyo University. He has been a visiting professor at Hitotsubashi University and Tokyo University in Japan, Imperial College in London, the University of St. Gallen in Switzerland, the University of Maryland, and Ludwig Maximilians University in Munich. Dr. Cusumano has consulted for some 90 companies around the world, including Alcatel, Amadeus, AOL, AT&T, BMC Software, Business Objects, Cisco, Ericsson, Fiat, Ford, Fujitsu, General Electric, Fidelity, Verizon, Hitachi, Huawei, i2 Technologies, IBM, Intel, Lucent, Motorola, NASA, NEC, Nokia, Nortel, NTT Data, Philips, Robert Bosch, Schlumberger, Siemens, Texas Instruments, and Toshiba. He has been a director of several public and private companies, including Patni Computer Systems (www.patni.com, an IT services firm sold to iGate-Apax in 2011 for $1.2 billion) as well as Eliza Corporation (www.elizacorp.com, a communications and voice-recognition solutions firm which brought in Parthenon Capital Partners as a gross investor in 2011). He is a currently a director of Fusion Storm Global (www.fusionstormglobal.com, an IT solutions provider). He is also on the advisory board of Fixstars Corp. (www.fixstars.com, a developer of high-performance computing applications), and several other companies and organizations. He has also served as editor-in-chief and chairman of the MIT Sloan Management Review and writes a column on Technology Strategy and Management for Communications of the ACM. He was named one of the most influential people in technology and IT by Silicon.com in 2009. Professor Cusumano has published 9 books. His newest book, Staying Power: Six Enduring Principles for Managing Strategy and Innovation in an Uncertain World (2010), is based on the 2009 Clarendon Lectures in Management Studies at Oxford University and is translated into Japanese, Chinese, and Italian. The Business of Software (2004) was named one of the best business books of the year by Steve Lohr of The New York Times and is translated into Japanese and Chinese. Microsoft Secrets (1995, with Richard Selby) is a best-selling study of Microsoft’s strategy, organization, and approach to software development, and has sold some 150,000 copies in 14 languages. Platform Leadership: How Intel, Microsoft, and Cisco Drive Industry Innovation (2002, with Annabelle Gawer) examines how industry leaders orchestrate complementary innovations that make their platforms more valuable. Competing on Internet Time: Lessons from Netscape and its Battle with Microsoft (1998, with David Yoffie), was named one of the top 10 business books of 1998 by Business Week and Amazon.com, and played a central role in the Microsoft anti-trust trial. Thinking Beyond Lean: How Multi-Project Management is Transforming Product Development at Toyota and Other Companies (1998, with Kentaro Nobeoka) analyzes product development and platform strategies in the auto industry. He is also co-editor of Strategic Thinking for the Next Economy (2001, with Costas Markides) and author of Japan’s Software Factories: A Challenge to U.S. Management (1991) and The Japanese Automobile Industry: Technology and Management at Nissan and Toyota (1985). About Quantum Leap Innovations: Quantum Leap Innovations, Inc. is the creator of the Quantum Leap® Pattern Based Analytics family of products which includes Pattern Based Discovery, Pattern Based Prediction, and Pattern Based Reasoning. Pattern Based Analytics is a powerful new approach to data analysis. It provides unique insights into the full complexity of real world data and it does this without either requiring deep mathematical skills or by requiring heroic simplifying assumptions about the important variables at work. The Quantum Leap Pattern Based Analytics suite of products enables transparent, flexible discovery, visualization and analysis of informative patterns in large, complex data environments. These characteristics empower the non-statistical subject matter expert to rapidly obtain insight into their data for discovery, forecasting and decision making. Quantum Leap is headquartered in the Delaware Technology Park which is affiliated with the University of Delaware and is located in Newark, Delaware. © 2015 Buyouts Insider / Argosy Group LLC
Quantum Leap Innovations Frequently Asked Questions (FAQ)
When was Quantum Leap Innovations founded?
Quantum Leap Innovations was founded in 1999.
Where is Quantum Leap Innovations's headquarters?
Quantum Leap Innovations's headquarters is located at 1 Innovation Way Newark, DE 19738, Newark.
What is Quantum Leap Innovations's latest funding round?
Quantum Leap Innovations's latest funding round is Dead.
Who are the investors of Quantum Leap Innovations?
Investors of Quantum Leap Innovations include Delaware Technology Park.
Who are Quantum Leap Innovations's competitors?
Competitors of Quantum Leap Innovations include Biolog, Oligomerix, Bloomage BioTech, Keryx Biopharmaceuticals, AvidBiotics and 12 more.
Compare Quantum Leap Innovations to Competitors

Biolog specializes in microbial identification, phenotypic cell profiling, and metabolic fingerprinting for microbial and mammalian cells. The company’s products enable the identification of thousands of species of bacteria, yeast, and fungi, as well as the characterization of human cells and mitochondria. Biolog's products are available worldwide, either directly from the company or through its extensive network of international distributors. The company was founded in 1984 and is based in Hayward, California.
ARCXIS develops, produces, and distributes portable biological diagnostic tools with the ability to analyze, detect, and characterize infectious disease agents. It develops diagnostic tools for use in national defense, clinical diagnostics, as well as food and beverage applications. The company was founded in 2004 and is based in Houston, Texas.
Spreading innovation in the Nano- and Biotechnology fields - this is the aim of Tethis. The company are heading for this goal through a tri-fold market approach reflected by the three business units of Tethis: Tethis Systems, Tethis Technology Services and Tethis Research. Tethis Systems focuses on the design and sale of nanoparticle synthesis and nanocoating units allowing customers to develop their own nanotech-products in-house. Tethis Technology Services supports customers with nano - and biotech product development by technical consulting and by opening Tethis' platform technologies for services such as tailor-made coatings or nanopowder development. Tethis Research targets on the incorporation of nanotechnology in devices, for instance by the integration of nanotechnology, biotechnology and microfabrication. Many of the company's research projects are based on collaborations with industries, universities and research centers reflecting the company's motto "Integration through collaboration".n
Protherics is an international biopharmaceutical company focused on specialist products for critical care and cancer.nThe Company has two critical care products, CroFab and DigiFab, approved for sale in the US. The Company has the opportunity to sell these products in the US from October 2010 together with Voraxaze, a supportive cancer care product, following anticipated approval in the US in 2010. Protherics is also developing a number of other products in the cancer arena that it can commercialise in-house.nIn addition, Protherics has several potential blockbuster products that require development and commercialisation partners. These include CytoFab which has been partnered by AstraZeneca in a major licensing deal, and also Angiotensin Therapeutic Vaccine and Digoxin Immune Fabs for which licensing partners will be sought in 2008-2009. These products have the potential to be high value products that can provide additional funding for the Company.n
Biomat is an engineering company, focused on surface modifications for biomedical applications. The company mission is to support life science manufacturers and researchers.
Dr. Alex Waldrop has developed AcriGlow-301TM to detect the presence of hydrogen peroxide by chemilumniescence for medical and environmental purposes. The European patent has issued for this chemiluminescent technology developed with co-inventor Dr. Calvin Vary of MMCRI (Maine Medical Center Research Institute). Used as a detection system, the process can be adapted to detect a wide variety of substances. Developed with support of MMCRI, Jane Havey of Capricorn Products and the Maine Center for Innovation and Biotechnology (CIBT, the predecessor to MTI), Dr Waldrop hopes to license the technology to clients in the fields of bio-technology and environmental detection. Various companies in the United States, in Japan and in Spain have used the product on a trial basis. The U.S. patent is still pending. This technology has been applied to antibody-based diagnostics.